Core Viewpoint - The company, 加科思-B (01167), has received notification from its concerted action members expressing strong confidence in the company's future development prospects, leading to significant share purchases and a share buyback program [1] Group 1: Share Purchases - From July 16, 2025, to the date of the announcement, concerted action members have collectively purchased 11,058,650 shares at a total cost of approximately HKD 96.34 million [1] - As of the announcement date, these members hold a total of 200 million shares, representing about 25.28% of the company's total issued shares [1] Group 2: Share Buyback - Since July 15, 2025, the company has repurchased a total of 326,400 shares, with a cumulative payment of HKD 2.67 million [1] - The company plans to continue monitoring market conditions and may exercise shareholder authorization for further share repurchases based on market circumstances [1] Group 3: Business Outlook - The company reports that its current business operations are performing well, with encouraging progress in the research and development of its core product pipeline, including the Pan-KRAS inhibitor [1] - The management's substantial share purchases and the company's share buyback actions reflect a strong confidence in the company's fundamentals and long-term growth prospects [1]
加科思-B(01167)获一致行动人士合共增持1105.865万股 涉资约9634万港元